Mr Chad E. Davis > Dechert LLP > Boston, United States > Lawyer Profile

Dechert LLP
BOSTON, MA 02110-2605
United States
Chad E. Davis photo

Work Department

Intellectual Property


Dr. Chad E. Davis counsels companies, investors, and entrepreneurs on intellectual property matters, especially patent matters. Dr. Davis has extensive experience in prosecution and strategic development of worldwide patent portfolios, intellectual property due diligence, risk assessment through, for example, validity and infringement analyses, post-grant patent proceedings, and intellectual property contracts.

Dr. Davis represents clients in a diverse range of technologies, including pharmaceuticals, drug delivery technologies, crystal forms, organic dyes, chemical processes, polymers, proteins, antibodies, stem cell technology, medical diagnostics, medical imaging, microfluidic devices, adhesives, analytical chemistry, foams, cosmetics, and optical technologies.  For companies developing pharmaceuticals, Dr. Davis provides counsel through all aspects of the business cycle with particular acumen for developing and implementing strategies to maximize worldwide patent and regulatory exclusivities for the pharmaceutical product.


American Chemical Society; American Intellectual Property Law Association; Intellectual Property Owners Association


Ball State University, B.S., 1998, summa cum laude; University of Illinois at Urbana-Champaign, Ph.D., Chemistry, 2003; Boston College Law School, J.D., 2007

Lawyer Rankings

United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)

(Leading lawyers)

Chad Davis – Dechert LLP

Dechert LLP‘s Boston-based practice is co-led by Andrea Reid and Andrew Wilkins, who is described as ‘one of the best IP counsel’. The team is adept at advising on prosecution in a multitude of areas, though there is an evident expertise across the board in biotech, with the team being noted as a ‘terrific partner when it comes to new technologies’. Additionally, its work in life sciences and pharmaceuticals is noteworthy, a key example being Reid and the ‘business-centric’ and ‘excellent’ Chad Davis representing AVEO Oncology on the $566m multi-jurisdictional creation of its patent portfolio following its acquisition by LG Chem. Scott Warren  left the firm in August 2022.